Serum Protein Expression Predicts Recurrence in Patients With Early-Stage Lung Cancer After Resection

Annals of Thoracic Surgery

Volumn 81, Issue 6, 2006, Pages 1982-1987

  D'Amico, Thomas A ^a   Brooks, Kelli R ^a   Joshi, Mary Beth Moore ^a   Conlon, Debbi ^a   Herndon II, James ^a   Petersen, Rebecca P ^a   Harpole Jr , David H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HERMES ANTIGEN; SCATTER FACTOR; TUMOR MARKER; UROKINASE; UROKINASE RECEPTOR; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; E-SELECTIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTOR 2; FOLLOW-UP STUDIES; HEPATOCYTE GROWTH FACTOR; HUMANS; LIFE TABLES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PNEUMONECTOMY; POSTOPERATIVE PERIOD; PREDICTIVE VALUE OF TESTS; RECEPTORS, CELL SURFACE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33646843566     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2006.01.042     Document Type: Article

References (24)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics 2005. Ca Cancer J Clin 55 (2005) 10-30
2. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 111 (1997) 1710-1717
3. Arriagada R., Bergman B., Dunant A., et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004) 351-360
4. Winton T.L., Livingston R., Johnson D., et al. Vinorelbine plus cisplatin vs. observation in resected non-small cell lung cancer. N Engl J Med 352 (2005) 2589-2597
5. D'Amico T.A., Massey M., Herndon J.E., et al. A biological risk model for stage I lung cancer. immunohistochemical analysis of 408 patients with use of ten molecular markers. J Thorac Cardiovasc Surg 117 (1999) 736-743
6. Cronauer M.V., Hittmair A., Eder I.E., et al. Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate. Prostate 31 (1997) 223-233
7. Gasparini G., Toi M., Gion M., et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89 (1997) 139-147
8. Watanabe H., Hori A., Seno M., et al. A sensitive enzyme immunoassay for human basic fibroblast growth factor. Biochem Biophys Res Commun 175 (1991) 229-235
9. Seir C., Stephens R., Bizik J., et al. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 58 (1998) 1843-1849
10. Kim S.J., Shiba E., Taguchi T., et al. Urokinase type plasminogen activator receptor is a novel prognostic factor in breast cancer. Anticancer Res 17 (1997) 1373-1378
11. Guo Y.-J., Liu G., Wang X., et al. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res 54 (1994) 422-426
12. Wielenga V.J.M., Heider K.H., Offerhaus J.A., et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 53 (1993) 4754-4756
13. Yamashita J., Ogawa M., Yamashita S., et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 54 (1994) 1630-1633
14. Siegfried J., Weissfeld L., Singh-Kaw P., Weyant F., Testa J., and Landreeneau R. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Cancer Res 57 (1997) 433-439
15. Narita T., Kawakami-Kimura N., Kasai Y., et al. Induction of E-selectin expression on vascular endothelium by digestive system cancer cells. J Gastroenterol 31 (1996) 299-301
16. Matsuura N., Narita T., Mitsuoka C., et al. Increased concentration of soluble E-selectin in the serum of breast cancer patients. Anticancer Res 17 (1997) 1367-1372
17. Hebbar M., Revillion F., Louchez M., et al. The relationship between concentrations of circulating soluble E-selectin and clinical, pathological, and biological features in patients with breast cancer. Clin Cancer Res 4 (1998) 373-380
18. Roselli M., Mineo T.C., Martini F., et al. Soluble selectin levels in patients with lung cancer. Int J Biolog Marker 17 (2002) 56-62
19. Tsumatori G., Ozeki Y., Takagi K., Ogata T., and Tanaka S. Relation between the serum E-selectin level and the survival rate of patients with resected non-small cell lung cancers. Jpn J Cancer Res 90 (1999) 301-307
20. Pretreatment evaluation of non-small-cell lung cancer. Official statement of The American Thoracic Society and The European Respiratory Society. Am J Respir Crit Care Med 156 (1997) 320-322
21. Sawabata N., Ohta M., Takeda S., et al. Serum carcinoembryonic antigen level in surgically resected clinical stage I patients with non-small cell lung cancer. Ann Thorac Surg 74 (2003) 174-179
22. Sadoff L. The usefulness of carcinoembryonic antigen testing in the overall management of patients with non-small-cell lung cancer. Am J Clin Oncol 21 (1998) 284-286
23. Okada M., Nishio W., Sakamoto T., et al. Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer. analysis of 1,000 consecutive resections for clinical stage I disease. Ann Thorac Surg 78 (2004) 216-221
24. Doeberitz M.K., and Lacroix J. Nucleic acid based techniques for the detection of rare cancer cells in clinical samples. Cancer Metas Rev 18 (1999) 43-64